WO2009067799A1 - Use of transglutaminase inhibitor in skin treatment - Google Patents
Use of transglutaminase inhibitor in skin treatment Download PDFInfo
- Publication number
- WO2009067799A1 WO2009067799A1 PCT/CA2008/002074 CA2008002074W WO2009067799A1 WO 2009067799 A1 WO2009067799 A1 WO 2009067799A1 CA 2008002074 W CA2008002074 W CA 2008002074W WO 2009067799 A1 WO2009067799 A1 WO 2009067799A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carrier
- skin
- transglutaminase inhibitor
- amount
- present
- Prior art date
Links
- 229940098113 Transglutaminase inhibitor Drugs 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims description 10
- 229940100611 topical cream Drugs 0.000 claims abstract description 13
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 239000005700 Putrescine Substances 0.000 claims abstract description 4
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 4
- 230000036556 skin irritation Effects 0.000 claims abstract description 4
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 19
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 4
- 239000011769 retinyl palmitate Substances 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 3
- 229940108325 retinyl palmitate Drugs 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical group 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000003679 aging effect Effects 0.000 abstract description 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 5
- 108060008539 Transglutaminase Proteins 0.000 description 4
- 102000003601 transglutaminase Human genes 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- -1 amine compound Chemical class 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940064888 aquasol a Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VMNZBBHWHOMWAQ-UHFFFAOYSA-N pentane-1,5-diamine Chemical compound NCCCCCN.NCCCCCN VMNZBBHWHOMWAQ-UHFFFAOYSA-N 0.000 description 1
- 230000016446 peptide cross-linking Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to skin treatment.
- transglutaminase inhibitors are useful for cosmetic purposes, specifically for the management of skin irritations and the inflammation and aging effects which result therefrom.
- transglutaminase inhibitors for cosmetic purposes, particularly for inhibiting aging of the skin.
- the present invention provides a topical cream containing a trasnglutaminase inhibitor, which is used in the method of the invention.
- the transglutaminase inhibitor is preferably putrescme(l,4-diaminobutane), a natural metabolite, although other known transglutaminase inhibitors may be used, such as aminoacetonitrile, cadaverine (1,5-diaminopentane) and spermidine, which are all primary amines.
- the topical cream is used for treating skin irritation caused by inflammation, which leads to aging of the skin.
- the topical cream therefore, can be used as a cosmetic for inhibiting aging of the skin.
- transglutaminase inhibitor in the form of a topical cream provides an ease of use for the patient and is cost-effective.
- composition of the invention is medicinal creams for the treatment of acne. Scarring due to skin breakouts occurs quite often and is linked to decreased self-esteem. Incorporation of a transglutaminase inhibitor into a cream to treat acne may prevent scarring from occurring.
- the cream may be formulated in any convenient manner suitable for topical application.
- the carrier for the active component may be a mineral base, such as polyglycol, mineral oil or ointment of silicon base, preferably silicon base, and the active component may be present in the cream in an amount of about 0.05 to about 1.0 % w/v of carrier, specifically about 0.8 % w/v.
- transglutaminase inhibitors in the topical cream may be combined with other anti-aging agents, such as retinoids, for example, trans-retinoic acid and retinol palmitate (Tazoral), and Vitamin A.
- additional anti-aging agents such as retinoids, for example, trans-retinoic acid and retinol palmitate (Tazoral)
- retinoids for example, trans-retinoic acid and retinol palmitate (Tazoral)
- Vitamin A may be used in an amount of about 0.1 to about 1 % w/v for Vitamin A and about 0.05 to about 0.1 wt % for retinoids.
- Fibrostat After 12 weeks, it was elected to use Fibrostat in an informed trial for off label use. It was completely healed within one week and stable within 3 weeks. She was discharged shortly thereafter.
- the present invention provides a topical cream useful for cosmetic purposes, particularly in the management of skin healing and inflammation. Modifications are provided within the scope of this invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Human skin is treated for cosmetic purposes, in particular for the management of skin irritation and/or inflammation as well as inhibiting ageing effects, which result therefrom by using a topical cream containing at least one transglutaminase inhibitor such as putrescine.
Description
TITLE OF INVENTION
USE OF TRANSGLUTAMINASE INHIBITOR IN SKIN TREATMENT
REFERENCE TO RELATED APPLICATION
[0001] This application claims priority pursuant to 35 USC 119(e) from US
Provisional Patent Application No. 60/996,622 filed November 27, 2007.
FIELD OF INVENTION
[0002] The present invention relates to skin treatment.
BACKGROUND OF THE INVENTION
[0003] I have previously described in U.S. Patent No. 5,885,982, a method of treating or preventing hypertrophic scar tissue in human skin by topically applying an effective amount of non-toxic amine compound which is a trans-glutaminase inhibitor having a free amine group. The amine compound that is a transglutaminase inhibitor is also selective for inhibiting Type III collagen peptide crosslinking. Treatment of hypertrophic scar generally includes the use of occlusive dressings, compression therapy, intralesional corticosteroid injections, surgical excision or cryotherapy.
SUMMARY OF INVENTION
[0004] I have now found that transglutaminase inhibitors are useful for cosmetic purposes, specifically for the management of skin irritations and the inflammation and aging effects which result therefrom.
[0005] Accordingly, in one aspect of the present invention, there is provided a method of treatment of skin using transglutaminase inhibitors for cosmetic purposes, particularly for inhibiting aging of the skin.
GENERAL DESCRIPTION OF INVENTION
[0006] The present invention provides a topical cream containing a trasnglutaminase inhibitor, which is used in the method of the invention. The transglutaminase inhibitor is preferably putrescme(l,4-diaminobutane), a natural metabolite, although other known transglutaminase inhibitors may be used, such as
aminoacetonitrile, cadaverine (1,5-diaminopentane) and spermidine, which are all primary amines.
[0007] The topical cream is used for treating skin irritation caused by inflammation, which leads to aging of the skin. The topical cream, therefore, can be used as a cosmetic for inhibiting aging of the skin.
[0008] The provision of the transglutaminase inhibitor in the form of a topical cream provides an ease of use for the patient and is cost-effective.
[0009] One area of potential use for a composition of the invention is medicinal creams for the treatment of acne. Scarring due to skin breakouts occurs quite often and is linked to decreased self-esteem. Incorporation of a transglutaminase inhibitor into a cream to treat acne may prevent scarring from occurring.
[0010] The cream may be formulated in any convenient manner suitable for topical application. The carrier for the active component may be a mineral base, such as polyglycol, mineral oil or ointment of silicon base, preferably silicon base, and the active component may be present in the cream in an amount of about 0.05 to about 1.0 % w/v of carrier, specifically about 0.8 % w/v.
[0011] The use of transglutaminase inhibitors in the topical cream may be combined with other anti-aging agents, such as retinoids, for example, trans-retinoic acid and retinol palmitate (Tazoral), and Vitamin A. When such additional anti-aging agents are present, they may be used in an amount of about 0.1 to about 1 % w/v for Vitamin A and about 0.05 to about 0.1 wt % for retinoids.
EXAMPLES
[0012] A number of case studies have been conducted with human patients, as described below:
[0013] Case l
[0014] This 68 year old female with known intrinsic allergies, presents with acute onset of blepharitis. She was seen by her family physician and was prescribed over the counter steroids and gentle cleansing.
[0015] The problem persisted for several weeks and, in fact, worsened in terms of redness and itching. The patient was treated with a topical cream in which putrescine (Sigma Chemical Co., St. Louis, MO) was compounded in an eutectic base (Glaxo Canola Ltd., Toronto, Ont.) at 0.8 % w/v concentration (15 niM) (Fibrostat) and within 24 hours, her symptoms subsided and the erythema and irritated skin resolved completely within another few days. The patient has remained well since.
[0016] Case 2
[0017] This 80 year old rheumatoid arthritic patient sustained a sacral pressure sore and required skin grafting to close the flap donor site. Her donor site failed to heal in spite of being taken off steroids but maintained on antibiotics. She received Aquasol A (a vitamin A preparation) and later mineral oil compresses while nursed in hospital to attempt healing the wound.
[0018] After 12 weeks, it was elected to use Fibrostat in an informed trial for off label use. It was completely healed within one week and stable within 3 weeks. She was discharged shortly thereafter.
[0019] Case 3
[0020] This 48 year old female had recently undergone a chemical peel with tricloroacetic acid. The patient complained of ulceration along the mandibular border which was itchy and weepy. A trial of betamethasone was ineffective in gaining relief and, after three days, she started on Fibrostat. Immediate changes were seen in terms of resolution of irritation. Repair was clearly evident the following day and by 5 days, the redness and ulceration had completely resolved.
[0021] Case 4
[0022] This 26 year old female undergone a resurfacing peel for deep acne scars using an Erbium YAG laser. When seen the following week, she remained quite red and ulcerated, in spite of prophylaxis with antiviral medication and ELTA cream. The itchiness was another concern. Therefore, she started on Fibrostat and she resolved over the next week to go on ultimately and heal without further problem.
[0023] Case 5
[0024] The issue of the male facelift patient and visible scarring was a concern for the next patient who was a 63 year old that had undergone a facelift and simultaneous Erbium YAG resurfacing of his eyelids. The eyelids were prophylactically treated with Fibrostat and were completely healed within one week of treatment. He went on to develop hypertrophic scars in front of his ears and these were later treated with laser resurfacing and post operation Fibrostat with no evidence of visibly recurrent scars.
[0025] These patients represent the benefit of topical cream containing putrescine in helping repair irritated tissue and its role in preventing visible scar formation through the recently reported inhibition of transforming growth beta conversion. Long term effects are likely due to rapid repair seen in the epithelium as well. Whether increased apoptosis is of benefit in achieving a stable scar in short term use or not is unknown. Certainly, the quality of the scars seen clinically in prophilatic use, may also represent the effects of the creams on matrix architecture through inhibition of collagen type III crosslinking.
SUMMARY OF DISCLOSURE
[0026] In summary of this disclosure, the present invention provides a topical cream useful for cosmetic purposes, particularly in the management of skin healing and inflammation. Modifications are provided within the scope of this invention.
Claims
1. A method for the treatment of human skin for cosmetic purposes, which comprises applying to the skin an effective amount of at least one transglutaminase inhibitor.
2. The method of claim 1 wherein said transglutaminase inhibitor is applied to the skin to inhibit aging of the skin.
3. The method of claim 1 wherein said transglutaminase inhibitor is applied to the skin for the management of skin irritation and/or the inflammation.
4. The method of claim 1 wherein said transglutaminase inhibitor is applied to the skin to the treatment of acne.
5. The method of claim 1 wherein said transglutaminase inhibitor is putrescine.
6. The method of claim 1 wherein said transglutaminase inhibitor is applied to the skin in the form of a topical cream.
7. The method of claim 6 wherein the topical cream comprises a carrier and the transglutaminase inhibitor.
8. The method of claim 7 wherein the carrier is a mineral base.
9. The method of claim 8 wherein the mineral base is a polyglycol, a mineral oil or a silicon base ointment.
10. The method of claim 7 wherein the transglutaminase inhibitor is present in the cream in an amount of about 0.05 to about 1.0 % w/v of carrier.
11. The method of claim 10 wherein the transglutaminase inhibitor is present in an amount of about 0.08% w/v of the carrier.
12. The method of claim 7 wherein the topical cream further comprises at least one additional anti-aging agent.
13. The method of claim 12 wherein the at least one additional anti-aging agent is a retinoid or Vitamin A.
14. The method of claim 13 wherein the retinoid is trans-retinoic acid or retinol palmitate.
15. The method of claim 13 wherein the retinoid is present in amount of about 0.05 to about 0.1% w/v of the carrier.
16. The method of claim 13 wherein the Vitamin A is present in an amount of about 0.1 to about 1% w/v of the carrier.
17. The use of a topical cream for cosmetic treatment of skin comprising at least one transglutaminase inhibitor and a carrier for said at least one transglutaminase inhibitor.
18. The use of claim 17 wherein the carrier ins a mineral base.
19. The use of claim 18 wherein the mineral base is a polyglycol, a mineral oil or a silicon base ointment.
20. The use of claim 19 wherein said at least one transglutaminase inhibitor is present in an amount of about 0.05 to about 1.0 % w/v of carrier.
21. The use of claim 20 wherein at least one the transglutaminase inhibitor comprises about 0.8% w/v of the carrier.
22. The use of claim 18 wherein the carrier further comprises at least one additional anti-aging agent.
23. The use of claim 22 wherein the at least one additional anti-aging agent is a retinoid or Vitamin A.
24. The use of claim 23 wherein the retinoid is trans-retinoic acid or retinol palmitate.
25. The use of claim 23 wherein the retinoid is present in amount of about 0.05 to about 0.1% w/v of the carrier.
6. The use of claim 23 wherein the Vitamin A is present in an amount of about 0.1 about 1% w/v of the carrier.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2706630A CA2706630A1 (en) | 2007-11-27 | 2008-11-27 | Use of transglutaminase inhibitor in skin treatment |
| US12/734,824 US20110034556A1 (en) | 2007-11-27 | 2008-11-27 | Use of transglutaminase inhibitor in skin treatment |
| EP08855190.8A EP2219594A4 (en) | 2007-11-27 | 2008-11-27 | Use of transglutaminase inhibitor in skin treatment |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99662207P | 2007-11-27 | 2007-11-27 | |
| US60/996,622 | 2007-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009067799A1 true WO2009067799A1 (en) | 2009-06-04 |
Family
ID=40677982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2008/002074 WO2009067799A1 (en) | 2007-11-27 | 2008-11-27 | Use of transglutaminase inhibitor in skin treatment |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110034556A1 (en) |
| EP (1) | EP2219594A4 (en) |
| CA (1) | CA2706630A1 (en) |
| WO (1) | WO2009067799A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018126321A1 (en) * | 2017-01-06 | 2018-07-12 | Vivier Canada Inc. | Putrescine topical barrier formulation |
| WO2018232527A1 (en) * | 2017-06-23 | 2018-12-27 | Vivier Canada Inc. | Putrescine topical formulations |
| WO2019232644A1 (en) * | 2018-06-08 | 2019-12-12 | Vivier Canada Inc. | Sterile topical saline putrescine formulation and uses thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042740A1 (en) * | 2016-11-21 | 2018-05-24 | Vivier Canada Inc. | Putrescine slow-release topical formulations |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603146A (en) * | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
| EP0237082A2 (en) * | 1986-03-14 | 1987-09-16 | Syntex (U.S.A.) Inc. | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| US4826828A (en) * | 1985-04-22 | 1989-05-02 | Avon Products, Inc. | Composition and method for reducing wrinkles |
| WO1999051213A2 (en) * | 1998-04-03 | 1999-10-14 | Theodore Toney Ilenchuk | The use of polyamines in the treatment of dermatological symptoms |
| WO2006048671A1 (en) * | 2004-11-05 | 2006-05-11 | Bioforskning As | Polyamine compositions |
| WO2007148739A1 (en) * | 2006-06-22 | 2007-12-27 | Toyo Boseki Kabushiki Kaisha | Cell activator, anti-aging agent and extracellular matrix production promoter derived from plant |
| JP2008156330A (en) * | 2006-04-26 | 2008-07-10 | Toyobo Co Ltd | Activating agent and anti-aging agent |
| JP2008239549A (en) * | 2007-03-27 | 2008-10-09 | Toyobo Co Ltd | Extracellular matrix production improver |
| JP2008239548A (en) * | 2007-03-27 | 2008-10-09 | Toyobo Co Ltd | Cell activator |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69232629T2 (en) * | 1992-03-23 | 2003-01-30 | Univ Manitoba Winnipeg | USE OF TRANSGLUTAMINASE INHIBITORS FOR THE TREATMENT OF SCAR TISSUE |
| EP0806947A4 (en) * | 1995-02-03 | 1998-10-14 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| FR2763853B1 (en) * | 1997-05-28 | 2000-01-07 | Oreal | ASSOCIATION OF A RETINOIDE WITH A POLYAMINE POLYMER |
-
2008
- 2008-11-27 WO PCT/CA2008/002074 patent/WO2009067799A1/en active Application Filing
- 2008-11-27 US US12/734,824 patent/US20110034556A1/en not_active Abandoned
- 2008-11-27 EP EP08855190.8A patent/EP2219594A4/en not_active Withdrawn
- 2008-11-27 CA CA2706630A patent/CA2706630A1/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603146A (en) * | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
| US4826828A (en) * | 1985-04-22 | 1989-05-02 | Avon Products, Inc. | Composition and method for reducing wrinkles |
| EP0237082A2 (en) * | 1986-03-14 | 1987-09-16 | Syntex (U.S.A.) Inc. | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors |
| WO1999051213A2 (en) * | 1998-04-03 | 1999-10-14 | Theodore Toney Ilenchuk | The use of polyamines in the treatment of dermatological symptoms |
| WO2006048671A1 (en) * | 2004-11-05 | 2006-05-11 | Bioforskning As | Polyamine compositions |
| JP2008156330A (en) * | 2006-04-26 | 2008-07-10 | Toyobo Co Ltd | Activating agent and anti-aging agent |
| WO2007148739A1 (en) * | 2006-06-22 | 2007-12-27 | Toyo Boseki Kabushiki Kaisha | Cell activator, anti-aging agent and extracellular matrix production promoter derived from plant |
| JP2008239549A (en) * | 2007-03-27 | 2008-10-09 | Toyobo Co Ltd | Extracellular matrix production improver |
| JP2008239548A (en) * | 2007-03-27 | 2008-10-09 | Toyobo Co Ltd | Cell activator |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP2219594A4 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018126321A1 (en) * | 2017-01-06 | 2018-07-12 | Vivier Canada Inc. | Putrescine topical barrier formulation |
| WO2018232527A1 (en) * | 2017-06-23 | 2018-12-27 | Vivier Canada Inc. | Putrescine topical formulations |
| WO2019232644A1 (en) * | 2018-06-08 | 2019-12-12 | Vivier Canada Inc. | Sterile topical saline putrescine formulation and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2706630A1 (en) | 2009-06-04 |
| EP2219594A1 (en) | 2010-08-25 |
| EP2219594A4 (en) | 2015-01-14 |
| US20110034556A1 (en) | 2011-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tung et al. | α-Hydroxy acid-based cosmetic procedures: Guidelines for patient management | |
| CA2121484C (en) | Treatment of acne or of pseudofolliculitis barbae | |
| US20110034556A1 (en) | Use of transglutaminase inhibitor in skin treatment | |
| US10202338B2 (en) | Topical compositions for the treatment of dermatological disorders | |
| US8846646B2 (en) | Topical treatment of skin infection | |
| US20130131177A1 (en) | Use of a dermatological composition comprising a combination of adapalene and benzoyl peroxide which is intended for the treatment of acne in non-caucasian population with decrease of post-inflammatory hyperpigmentation | |
| US20110201578A1 (en) | Composition and methods for the treatment of pseudofolliculitis barbae and skin irritation | |
| AU2007293500B2 (en) | Medicine for the treatment of acne and for reversing the signs of age and sun damage and method for using same | |
| EP2563357B1 (en) | Adapalene 0.3% for use in a method for treating scars | |
| US6051244A (en) | Fructose diphosphate topical compositions | |
| WO2017129108A1 (en) | Silica gel for use in treating skin diseases | |
| CA2762394C (en) | Topical retinoid solutions | |
| CN110769819A (en) | Cannabinoid formulations for the treatment of acne | |
| CN114028265A (en) | Supermolecule embedded salicylic acid and preparation method thereof | |
| US10071052B2 (en) | Method for the prevention and treatment of acne | |
| CN1478478A (en) | Medicinal composition for treating psoriasis | |
| AU8911198A (en) | Use of 17-alpha-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy | |
| US11458114B2 (en) | Methods and compositions for enhancing synthesis secretion and transport of collagen to increase wound strength | |
| CA2480225A1 (en) | Methods for treating rosacea with pyridones | |
| CN1528327A (en) | Complex external medicine speical for acne and preparing method thereof | |
| WO2020153855A1 (en) | Composition for use in the treatment of skin wound | |
| WO2000032155A2 (en) | Skin care compositions containing zinc salts and retinoids | |
| US20150209401A1 (en) | Synergistic Multi-Active Composition for Topical Treatment of Disorders in Mammals, Use of Composition, and Method | |
| Gamón et al. | Contact dermatitis from nitroglycerin in a transdermal therapeutic system | |
| Hunzelmann et al. | Evaluation and Management of Skin Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08855190 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2706630 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008855190 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12734824 Country of ref document: US |